Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet A Dunn

Showing results (21-30 of 59) with videos related to

Pageof 6
Sort By:
Blood Cancer Journal|November 5, 2020
Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient managementIlaria J Chicca, Jennifer L J Heaney, Gulnaz Iqbal, et al.
Plos One|September 4, 2020
Computational approaches to support comparative analysis of multiparametric tests: Modelling versus TrainingJohn M S Bartlett, Jane Bayani, Elizabeth N Kornaga, et al.
Breast Cancer Research : BCR|May 28, 2024
Optimising the diagnostic accuracy of First post-contrAst SubtracTed breast MRI (FAST MRI) through interpretation-training: a multicentre e-learning study, mapping the learning curve of NHS Breast Screening Programme (NHSBSP) mammogram readers using an enriched datasetLyn I Jones, Andrea Marshall, Rebecca Geach, et al.
The New England Journal of Medicine|July 27, 2007
Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancerDavid J Kerr, Janet A Dunn, Michael J Langman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2010
Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trialRachel S Midgley, Christopher C McConkey, Elaine C Johnstone, et al.
International Journal of Cancer|March 14, 2013
Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trialAlaa M Ali, Elena Provenzano, John M S Bartlett, et al.
Breast Cancer Research : BCR|July 30, 2022
Evaluating the effectiveness of abbreviated breast MRI (abMRI) interpretation training for mammogram readers: a multi-centre study assessing diagnostic performance, using an enriched datasetLyn I Jones, Andrea Marshall, Premkumar Elangovan, et al.
Health Technology Assessment (Winchester, England)|November 7, 2019
Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCTMark T Drayson, Stella Bowcock, Tim Planche, et al.
Journal of Thrombosis and Haemostasis : JTH|January 30, 2020
Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m)Andrea Marshall, Mark Levine, Catherine Hill, et al.
BMJ Oncology|June 24, 2025
Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD dataHelena M Earl, Louise Hiller, Janet A Dunn, et al.
Pageof 6

Showing results (21-30 of 59) with videos related to

Sort By:
Pageof 6
Blood Cancer Journal|November 5, 2020
Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient managementIlaria J Chicca, Jennifer L J Heaney, Gulnaz Iqbal, et al.
Plos One|September 4, 2020
Computational approaches to support comparative analysis of multiparametric tests: Modelling versus TrainingJohn M S Bartlett, Jane Bayani, Elizabeth N Kornaga, et al.
Breast Cancer Research : BCR|May 28, 2024
Optimising the diagnostic accuracy of First post-contrAst SubtracTed breast MRI (FAST MRI) through interpretation-training: a multicentre e-learning study, mapping the learning curve of NHS Breast Screening Programme (NHSBSP) mammogram readers using an enriched datasetLyn I Jones, Andrea Marshall, Rebecca Geach, et al.
The New England Journal of Medicine|July 27, 2007
Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancerDavid J Kerr, Janet A Dunn, Michael J Langman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2010
Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trialRachel S Midgley, Christopher C McConkey, Elaine C Johnstone, et al.
International Journal of Cancer|March 14, 2013
Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trialAlaa M Ali, Elena Provenzano, John M S Bartlett, et al.
Breast Cancer Research : BCR|July 30, 2022
Evaluating the effectiveness of abbreviated breast MRI (abMRI) interpretation training for mammogram readers: a multi-centre study assessing diagnostic performance, using an enriched datasetLyn I Jones, Andrea Marshall, Premkumar Elangovan, et al.
Health Technology Assessment (Winchester, England)|November 7, 2019
Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCTMark T Drayson, Stella Bowcock, Tim Planche, et al.
Journal of Thrombosis and Haemostasis : JTH|January 30, 2020
Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m)Andrea Marshall, Mark Levine, Catherine Hill, et al.
BMJ Oncology|June 24, 2025
Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD dataHelena M Earl, Louise Hiller, Janet A Dunn, et al.
Pageof 6